IRCT20210801052044N1已完成未知
Evaluation of the humoral response in patients receiving half doses of AstraZeneca and BNT162b2 vaccines in a heterogenous prime-boost schedule.
Invicta Research and Development Center0 个研究点目标入组 20 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 55 years（—）
- 性别
- All
入选标准
- •Willingness to take part in the clinical trial
- •Age between 18 and 55 years old
排除标准
- •Age above 55 years old
- •Diagnosed with diabetes, hypertension, heart disease, chronic pulmonarydiseases, severe allergies
- •Obesity as defined by BMI > 30
研究者
相似试验
已完成
不适用
Evaluation of humoral immune response induced by a supplemental dose of inactivated poliovirus vaccine (IPV) administered intradermally or intramuscularly versus a dose of monovalent type 1 oral poliovirus vaccineISRCTN90744784Panacea Biotec Limited (India)1,000
已完成
不适用
Assessment of the humoral immune response and safety of reduced doses of influenza vaccine administered intradermally compared to intramuscular administratioInfections and InfestationsInfluenzaISRCTN33950739Berna Biotech AG, Crucell Company (Switzerland)275
已完成
不适用
The difference in full mouth implant placement in one session and multiple visitsDental Implant.Presence of tooth-root and mandibular implantsZ96.5IRCT20221110056464N1Tabriz University of Medical Sciences60
进行中（未招募）
1 期
Evaluation of immunological response following a revaccination with a non-conjugated pneumococcal vaccine boosted or not by a conjugated pneumococcal vaccine in splenectomised patients (SPLENEVAC-2)Asplenic patients at risk for invasive pneumococcal diseasesMedDRA version: 20.0Level: PTClassification code 10041642Term: SplenectomySystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2018-003068-29-FRASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)56
已完成
不适用
Examine the patient's response and symptom improvement using the Integrated Approach to Symptom Management Model for the patients who has oral mucositis associated with hematologic cancer therapyhematological malignancies oral mucositis associated with cancer therapyJPRN-UMIN000016948niversity of Hyogo20